Nov 9 (Reuters) - An AstraZeneca (AZN.L), opens new tab executive said he felt encouraged by "incredibly promising" COVID-19 vaccine trial data unveiled by Pfizer and its German partner BioNTech, ...
LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...
Major global pharmaceutical companies are significantly boosting their U.S. manufacturing capacities in response to potential ...
Amid looming 100% tariffs on imported drugs by the Trump administration, global pharmaceutical companies are significantly ...
The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular franchises. For example, sales of Tagrisso, an EGFR inhibitor for the ...
Parabilis Medicines raised $305 million in a Series F round led by RA Capital, Fidelity and Janus Henderson, with crossover investors like Janus and Cormorant. Insilico Medicine raised $292 million in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results